{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liao W"],"funding":["Science and Technology Department of Sichuan Province Funding Project"],"pagination":["17588359241274625"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11412210"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16"],"pubmed_abstract":["<h4>Background</h4>The HIMALAYA trial found that durvalumab plus tremelimumab significantly prolonged progression-free survival and overall survival in patients with unresectable hepatocellular carcinoma (HCC) compared with sorafenib.<h4>Objective</h4>This study aimed to investigate the cost-effectiveness of durvalumab plus tremelimumab compared with sorafenib in the first-line HCC setting.<h4>Design</h4>A Markov model-based cost-effectiveness analysis.<h4>Methods</h4>We created a Markov model to compare healthcare costs and clinical outcomes of HCC patients treated with durvalumab plus tremelimumab in the first-line setting compared with sorafenib. We estimated transition probabilities from randomized trials. Lifetime direct healthcare costs, quality-adjusted life-years (QALYs), and incre"],"journal":["Therapeutic advances in medical oncology"],"pubmed_title":["Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma."],"pmcid":["PMC11412210"],"funding_grant_id":["2016FZ0108, 18ZDYF1981"],"pubmed_authors":["Yang Y","Feng M","Li J","Hutton D","Wu Q","Liao W","Lei W","Bai L","Li Q","Xu H"],"additional_accession":[]},"is_claimable":false,"name":"Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma.","description":"<h4>Background</h4>The HIMALAYA trial found that durvalumab plus tremelimumab significantly prolonged progression-free survival and overall survival in patients with unresectable hepatocellular carcinoma (HCC) compared with sorafenib.<h4>Objective</h4>This study aimed to investigate the cost-effectiveness of durvalumab plus tremelimumab compared with sorafenib in the first-line HCC setting.<h4>Design</h4>A Markov model-based cost-effectiveness analysis.<h4>Methods</h4>We created a Markov model to compare healthcare costs and clinical outcomes of HCC patients treated with durvalumab plus tremelimumab in the first-line setting compared with sorafenib. We estimated transition probabilities from randomized trials. Lifetime direct healthcare costs, quality-adjusted life-years (QALYs), and incre","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-06-03T23:45:36.218Z","creation":"2025-04-07T07:33:30.011Z"},"accession":"S-EPMC11412210","cross_references":{"pubmed":["39301138"],"doi":["10.1177/17588359241274625"]}}